Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by eric40on Apr 02, 2019 12:09am
225 Views
Post# 29567697

RE:RE:RE:The PPPS

RE:RE:RE:The PPPSThe next ppps plan that will extract IVIG and who knows maybe more protein will be a copy cat of Laval with maybe some ajustment. So no big deal. 

The thing is once the BLA will be given to Laval plan, it will be for Ryplazim only. If there would be another protein like IVIG produce in Laval, it would automatically impact the plasminogen BLA and would require a new approuval for both protein produce in the same plan.

The BLA locks the process of a plan.

So the idea is to build another facility in an existhing approuved building like winnipeg or Belleville and do a new BLA application for that facility made for IVIG and another high value protein based on the Laval Plan.

This way, once they get the Pg BLA, Laval stays operational for the production of plasminogen and bring revenu that allow to start a new facility (and BLA process) and once the new facility and protein approved, the plasminogen is extract from the plasma in Laval and then the plasma is transfert in the other facility to extract the new approved protein like ivig or aat or else.

 
Bullboard Posts